Rigel Pharmaceuticals, Inc.
RIGL
NASDAQ1.40
Rigel Pharmaceuticals, Inc.
NASDAQ:RIGL
RECENT
PRICE
1.40
P/E
RATIO
-5.14
(PEG:0.02)
P/E RATIO
RELATIVE
TO S&P
-0.21
DIV
YLD
0.00%
High:
Low:
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Legends
Stock price
0.72 Beta (1.0 Market)
0
0
0
0
0
0
0
0
0
% total return 06/23:
Stock
S&P
1y.
0
0
3y.
0
0
5y.
0
0
0
Percent shares traded:
0
0
0
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
Fiscal year
0.44
(2.57)
(1.84)
- -
- -
(3.67)
(2.94)
- -
0.02
(2.73)
(2.52)
- -
2.40
0.73
0.83
- -
0.08
(1.36)
(1.13)
- -
0.03
(1.32)
(1.18)
- -
0.08
(1.02)
(1.00)
- -
0.09
(1.04)
(0.80)
- -
0.33
(0.58)
(0.27)
- -
0.22
(0.73)
(0.81)
- -
0.04
(0.62)
(0.62)
- -
0.28
(0.44)
(0.37)
- -
0.35
(0.40)
(0.26)
- -
0.64
(0.18)
(0.32)
- -
0.88
(0.11)
0.03
- -
0.70
(0.34)
(0.43)
- -
0.98
(0.27)
(0.40)
- -
Revenue per share
Earnings per share
Free Cash Flow per sh
Dividends per share
0.03
2.84
0.07
2.89
0.00
2.69
0.07
3.19
0.04
3.73
0.05
3.86
0.01
2.39
0.00
1.46
0.01
1.03
0.01
0.58
0.00
0.80
0.01
0.68
0.01
0.32
0.01
0.20
0.00
0.18
0.00
(0.08)
0.00
0.08
CAPEX per share
Book Value per share
29
36
41
52
63
75
87
88
88
94
126
161
167
169
169
172
129
Comm.Shares outs.(m)
(4.2)
(0.2)
- -
(5.3)
(0.2)
- -
(2.9)
(0.0)
- -
11.0
0.5
- -
(5.7)
(0.4)
- -
(6.8)
(0.5)
- -
(4.5)
(0.3)
- -
(2.8)
(0.2)
- -
(5.5)
(0.3)
- -
(3.7)
(0.2)
- -
(4.7)
(0.2)
- -
(7.7)
(0.3)
- -
(5.5)
(0.2)
- -
(13.9)
(0.4)
- -
(34.9)
(1.2)
- -
(5.2)
(0.2)
- -
(5.1)
(0.2)
- -
Avg. annual P/E ratio
P/E relative to S&P500
Avg. annual div. yield
Capital Structure (31/3/23 | Q1)
Total liabilities
$46 m.
Total assets
$124 m.
Long-term debt
$1 m.
Cash and equiv.
$40 m.
Goodwill - -
Retained earnings $(1,396) m.
Common stock - -
Market Capitalisation
$243 m. (as of 4/6/23)
2
(4,416.8)%
7
(1,251.3)%
8
(1,106.0)%
29
(179.1)%
20
(342.2)%
4
(1,775.6)%
45
(163.3)%
59
(116.5)%
109
(26.7)%
149
(8.4)%
120
(46.2)%
127
(43.1)%
Revenue (m)
Operating margin
2
(99)
3
(89)
2
(91)
1
(51)
1
(69)
0
(78)
1
(70)
1
(67)
1
(30)
1
(18)
1
(59)
1
(47)
Depreciation (m)
Net profit (m)
- -
(4,392.9)%
- -
(1,245.1)%
- -
(1,101.9)%
- -
(178.1)%
- -
(339.6)%
- -
(1,739.3)%
- -
(158.3)%
- -
(112.8)%
- -
(27.4)%
(3.5)%
(12.0)%
- -
(48.7)%
8.8%
(48.5)%
Income tax rate
Net profit margin
290
- -
289
210
- -
208
137
- -
128
95
- -
91
54
- -
55
99
- -
101
109
- -
110
61
10
54
48
30
34
91
21
30
51
1
(14)
61
1
77
Working capital (m)
Long-term debt (m)
Equity (m)
(33.2)%
(31.9)%
(34.2)%
(41.3)%
(39.4)%
(42.7)%
(64.9)%
(59.0)%
(70.9)%
(52.5)%
(39.1)%
(56.3)%
(124.6)%
(88.6)%
(125.8)%
(77.4)%
(65.5)%
(77.5)%
(63.3)%
(50.7)%
(64.1)%
(74.5)%
(45.1)%
(124.3)%
(40.8)%
(25.7)%
(87.4)%
(12.4)%
(7.4)%
(59.0)%
(79.4)%
(40.9)%
430.2%
(47.4)%
(32.8)%
(61.2)%
ROIC
Return on capital
Return on equity
Working Capital
2020
2021
2022
Cash assets
57
46
51
Receivables
16
15
40
Inventory
2
7
9
Other
14
7
8
Current assets
89
154
116
Acc. Payable
4
4
23
Debt due
9
10
1
Other
29
50
42
Current liab.
41
64
65
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
Plowback ratio
Div.&Repurch. to FCF
Rigel Pharmaceuticals, Inc. (US) started trading on November 3, 2000 (cik: 0001034842), operates in the Healthcare sector (Biotechnology industry), has 155 full-time employees, and is led by Mr. Raul R. Rodriguez. Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Annual rates
(avg rate of change)
Past
5 y.
Past
10 y.
Revenues
33.59%
131.68%
Cash flow
-406.74%
-168.21%
Earnings
31.64%
13.65%
Dividends
- -
- -
Book value
-60.84%
-28.69%
Insider trading
Type
Shares
Date
Rodriguez Raul R
Award
300,000
01/26/23
Rodriguez Raul R
Sale
20,340
02/06/23
Rodriguez Raul R
Award
600,000
01/26/23
Santos David A
Sale
5,388
02/02/23
Schorno Dean L
Sale
5,389
02/02/23
Fiscal Year Ends
Quarterly Revenue (m)
Full fiscal year
I
II
III
IV
2021
81
26
22
20
149
2022
17
30
22
51
120
2023
24
- -
- -
- -
- -
Fiscal Year Ends
Earnings per share
Full fiscal year
I
II
III
IV
2021
0.23
(0.08)
(0.12)
(0.13)
-0.11
2022
(0.17)
(0.08)
(0.11)
- -
-0.36
2023
(Infinity)
- -
- -
- -
- -
Fiscal Year Ends
Quarterly dividends paid
Full fiscal year
I
II
III
IV
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -